The Prognostic Value of Cancer Stem Cell Markers in Cervical Cancer: A Systematic Review and Meta-Analysis

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2021 Dec 30

PMID 34967589

Citations 11

Authors

Moh Nailul Fahmi

Inge Nandya Hertapanndika

Fitriyadi Kusuma

Affiliations

Soon will be listed here.

Abstract

Objectives: Prognostic biomarkers in cervical cancer are widely investigated, including cancer stem cell (CSC) markers. However, their significance remains uncertain. This study aimed to determine the role of cervical cancer stem cell (CCSC) markers for survival.

Materials And Methods: We conducted a systematic review and meta-analysis (PROSPERO CRD42021237072) of studies reporting CCSC markers as the prognostic predictor based on PRISMA guidelines. We included English articles investigating associations of CCSCs expression in tissue tumor with overall survival (OS) or disease-free survival (DFS) from PubMed, EBSCO, and The Cochrane Library databases. The quality of studies was analyzed based on Newcastle-Ottawa Quality Assessment Scale.

Results: From 413 publications, after study selection with inclusion and exclusion criteria, 22 studies were included. High expressions of CCSC markers were associated with poor OS and DFS (HR= 1.05, 95% CI: 1.03 - 1.07, P <0.0001; HR= 1.31, 95% CI: 1.09 - 1.17, P <0.00001; respectively). Sub-analysis of individual CCSC markers indicated significant correlations between CD44 (HR= 1.14, 95% CI: 1.07 - 1.22, P 0.0001), SOX2 (HR= 1.58, 95% CI: 1.17 - 2.14, P 0.003), OCT4 (HR= 1.03, 95% CI: 1.01 - 1.06, P 0.008), ALDH1 (HR= 1.36, 95% CI: 1.13 - 1.64, P 0.001), and CD49f (HR= 3.02, 95% CI: 1.37 - 6.64, P 0.006) with worse OS; OCT4 (HR= 1.14, 95% CI 1.06 - 1.22, P 0.0003), SOX2 (HR= 1.11, 95% CI: 1.06 - 1.16, P <0.0001), and ALDH1 (HR= 1.22, 95% CI: 1.10 - 1.35, P 0.0002) with poor DFS. We did not conduct a meta-analysis for MSI-1 and CK17 because only one study investigated those markers.

Conclusion: Expressions of OCT4, SOX2, and ALDH1 were associated with poor OS and DFS in cervical cancer tissue. These markers might have potential roles as prognostic biomarkers to predict unfavorable survival.

Citing Articles

CD133/ABCC5 cervical cancer cells exhibit cancer stem cell properties.

He L, Qian H, Seyiti A, Yang C, Shi N, Chen C Heliyon. 2024; 10(17):e37066.

PMID: 39296204 PMC: 11408061. DOI: 10.1016/j.heliyon.2024.e37066.

Association of CD133, ALDH1, CD117 and OCT4 expression with prognosis of patients with cervical cancer.

Almeida T, Dos Santos O, Saddi V, Pereira J, Machado H, Santos Carneiro M Virchows Arch. 2024; .

PMID: 38981932 DOI: 10.1007/s00428-024-03862-0.

Highlighting the role of CD44 in cervical cancer progression: immunotherapy's potential in inhibiting metastasis and chemoresistance.

de Sousa C, Eksteen C, Riedemann J, Engelbrecht A Immunol Res. 2024; 72(4):592-604.

PMID: 38816670 PMC: 11347469. DOI: 10.1007/s12026-024-09493-6.

EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria.

Orekoya A, Abdus-Salam A, Oyesegun A, Ntekim A, Folasire A, Okolo C Ecancermedicalscience. 2024; 17:1607.

PMID: 38414930 PMC: 10898916. DOI: 10.3332/ecancer.2023.1607.

Unveiling diagnostic and therapeutic strategies for cervical cancer: biomarker discovery through proteomics approaches and exploring the role of cervical cancer stem cells.

Jafari A, Farahani M, Abdollahpour-Alitappeh M, Manzari-Tavakoli A, Yazdani M, Rezaei-Tavirani M Front Oncol. 2024; 13:1277772.

PMID: 38328436 PMC: 10847843. DOI: 10.3389/fonc.2023.1277772.

References

Castelli G, Pelosi E, Testa U . Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel). 2017; 9(9). PMC: 5615342. DOI: 10.3390/cancers9090127. View

Rao Q, Yao T, Zhang B, Lin R, Chen Z, Zhou H . Expression and functional role of ALDH1 in cervical carcinoma cells. Asian Pac J Cancer Prev. 2012; 13(4):1325-31. DOI: 10.7314/apjcp.2012.13.4.1325. View

Muralikrishnan V, Hurley T, Nephew K . Targeting Aldehyde Dehydrogenases to Eliminate Cancer Stem Cells in Gynecologic Malignancies. Cancers (Basel). 2020; 12(4). PMC: 7225959. DOI: 10.3390/cancers12040961. View

Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T . Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol. 2001; 155(5):755-62. PMC: 2150876. DOI: 10.1083/jcb.200108159. View

Dobbin Z, Landen C . Isolation and characterization of potential cancer stem cells from solid human tumors--potential applications. Curr Protoc Pharmacol. 2014; 63:14.28.1-14.28.19. PMC: 4041697. DOI: 10.1002/0471141755.ph1428s63. View

Lohberger B, Rinner B, Stuendl N, Absenger M, Liegl-Atzwanger B, Walzer S . Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PLoS One. 2012; 7(8):e43664. PMC: 3426519. DOI: 10.1371/journal.pone.0043664. View

Linge A, Lohaus F, Lock S, Nowak A, Gudziol V, Valentini C . HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium.... Radiother Oncol. 2016; 121(3):364-373. DOI: 10.1016/j.radonc.2016.11.008. View

Hou T, Zhang W, Tong C, Kazobinka G, Huang X, Huang Y . Putative stem cell markers in cervical squamous cell carcinoma are correlated with poor clinical outcome. BMC Cancer. 2015; 15:785. PMC: 4619529. DOI: 10.1186/s12885-015-1826-4. View

Ngan C, Yamamoto H, Seshimo I, Ezumi K, Terayama M, Hemmi H . A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J Surg Oncol. 2007; 95(8):652-62. DOI: 10.1002/jso.20638. View

10.

Yang Y, Wang Y, Yin C, Li X . Clinical significance of the stem cell gene Oct-4 in cervical cancer. Tumour Biol. 2014; 35(6):5339-45. DOI: 10.1007/s13277-014-1696-4. View

11.

Yan Y, Zuo X, Wei D . Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med. 2015; 4(9):1033-43. PMC: 4542874. DOI: 10.5966/sctm.2015-0048. View

12.

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

13.

Liu X, Yang W, Xu R, Liu J, Zheng P . Cervical cancer cells with positive Sox2 expression exhibit the properties of cancer stem cells. PLoS One. 2014; 9(1):e87092. PMC: 3904967. DOI: 10.1371/journal.pone.0087092. View

14.

Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H . CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 2012; 72(13):3414-23. DOI: 10.1158/0008-5472.CAN-12-0299. View

15.

Liu H, Wang Y, Bian L, Fang Z, Zhang Q, Cheng J . CD44+/CD24+ cervical cancer cells resist radiotherapy and exhibit properties of cancer stem cells. Eur Rev Med Pharmacol Sci. 2016; 20(9):1745-54. View

16.

Signore M, Ricci-Vitiani L, De Maria R . Targeting apoptosis pathways in cancer stem cells. Cancer Lett. 2011; 332(2):374-82. DOI: 10.1016/j.canlet.2011.01.013. View

17.

Li J, Feng Z, Yeung F, Wong M, Oakie A, Fellows G . Aldehyde dehydrogenase 1 activity in the developing human pancreas modulates retinoic acid signalling in mediating islet differentiation and survival. Diabetologia. 2013; 57(4):754-64. DOI: 10.1007/s00125-013-3147-y. View

18.

Ji J, Wei X, Wang Y . Embryonic stem cell markers Sox-2 and OCT4 expression and their correlation with WNT signal pathway in cervical squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7(5):2470-6. PMC: 4069924. View

19.

Yoon H, Cha J, Keum K, Lee H, Nam E, Kim S . Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis. Radiat Oncol. 2015; 10:18. PMC: 4311470. DOI: 10.1186/s13014-014-0320-5. View

20.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2011; 3(3):e123-30. PMC: 3090117. View